Who are Element Biosciences' biggest competitors?

Illumina is the dominant incumbent and the main source of pressure, currently suing and being sued by Element while also able to cut prices to defend its share. Beyond Illumina, Element competes with other sequencing challengers including Singular Genomics (G4 benchtop platform), Ultima Genomics (wafer-based UG 100), and MGI/Complete Genomics, all trying to erode Illumina's position with new chemistry or hardware. As of the July 2026 assessment, none of these smaller rivals is documented as actively pulling customers away from Element itself.

Is Element Biosciences in financial trouble?

There's no evidence of imminent financial trouble as of the July 2026 assessment: Element's 2023 annual revenue exceeded $25M, its Series D topped $277M in mid-2024, and Samsung added $175M in a Series E round as of June 9, 2026. Cash burn is still flagged as an unresolved factor in its overall too-close-to-call standing, so the situation bears watching rather than being settled either way.

Is Element Biosciences at risk from AI?

AI does not appear to be a threat to Element Biosciences; the assessment lists its AI threat status as not applicable. If anything, AI models need more genomic data to train on, which tends to grow rather than shrink demand for sequencing platforms like AVITI and VITARI.

Can Illumina copy or crush Element Biosciences?

Illumina could try to copy elements of Element's approach, and the giant-threat status is marked as shipped, meaning Illumina has already moved to compete directly through litigation and pricing. However, Element has genuine legal cover: it won a German patent injunction against Illumina on July 14, 2026, and survived a US antitrust suit that was dismissed on May 28, 2026, with precedent for challengers beating Illumina in court, as MGI/Complete Genomics won a $333.8M verdict in 2024.

Biotech tools companies · United States

Element Biosciences

elementbiosciences.com ↗

Makes AVITI benchtop DNA sequencers challenging Illumina's grip on genomics.

Losing its protection

Assessed 30 July 2026 · Evidence as of 30 July 2026

The structural protection is eroding.

On the recordSince 30 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Illumina's appeal of the German court ruling and AVITI Dx/VITARI commercial launch

The call

Element has real chemistry and a court win, but its patent shield fades in 2028 while Illumina, Roche, and Ultima all chase the same price point.

Element Biosciences builds machines that read DNA quickly and cheaply. The company has patented chemistry and design rules that give it some legal protection, plus customers who buy its supplies over time, which normally makes it hard to dislodge. But Illumina, which controls most of the market already, is fighting back in court and with competing products, and well-funded rivals like Ultima, Roche, and PacBio are all chasing the same $100 to $150 price target at the same time. Element's key patents expire in January 2028, and its medical-use products for clinics have not yet shipped or proved they work in the real world. The next 12 months will tell the story: if Element can win approval in Europe and start selling its medical sequencers to hospitals, and if its testing products survive price pressure from Roche and Ultima, it has a shot at survival; if those products stay stuck in paperwork or lose the price war, the company runs out of runway.

Why

AI pressure: None apparent. AI drives more genomic data generation, which feeds sequencer demand rather than replacing it. Could AI do the core job? Unlikely.

Bigger players: Illumina. Illumina still holds most of the sequencing market and is appealing the July 2026 German ruling that lifted its injunction on Element. Could a giant copy it? Probably.

What protects it. Avidite chemistry patents, ISO 13485 certification, and consumables lock-in, plus a July 2026 German court win over Illumina.

What would change this call

Whether AVITI Dx receives EU CE-IVD filing and posts real diagnostic revenue by mid-2027. Shows if Element's clinical diagnostics push is real or stalled.
Outcome of Illumina's appeal of the July 2026 German court ruling. Determines if Element's patent-based legal shield against Illumina holds.
Whether Element's Series E closes on announced terms including the $175M Samsung investment. Indicates whether Element's funding runway and investor confidence remain intact.

Key numbers

$175M Samsung investment in upsized Series E (2026-06-09)
>$25M revenue in 2023, last confirmed figure (2024-01-08)
Core asserted patents expire January 2028 (2026-07-30)

Named risks

Core asserted German patent expires January 30, 2028, narrowing Element's litigation leverage over Illumina. Severity: high
Roche, Ultima, PacBio, and Complete Genomics simultaneously converging on the same $100 to $150 genome target. Severity: high
AVITI Dx and VITARI remain unshipped commercially and unproven against rival launches as of mid 2026. Severity: medium
Upsized Series E announced June 2026 remained subject to regulatory approval, not yet fully closed. Severity: medium
Illumina retains right to appeal the July 2026 German injunction, which could be overturned. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Illumina	contesting	Element won German injunction against Illumina MiSeq/MiSeqDx on 2026-07-14, litigation ongoing in US courts
Ultima Genomics	contesting	Both firms target sub $100 genome pricing around AGBT 2026 (March 2026)
Roche	gaining on	Roche launched Axelios 1 nanopore sequencer with list pricing implying ~$150 genome in February 2026
PacBio	contesting	PacBio's Onso and Revio compete in long-read/benchtop niche as of 2026 AGBT coverage
Complete Genomics	contesting	DNBSeq-T7+ pending US market entry pending ownership review, per March 2026 reporting

Questions people ask

Who are Element Biosciences' biggest competitors?: Illumina is the dominant incumbent and the main source of pressure, currently suing and being sued by Element while also able to cut prices to defend its share. Beyond Illumina, Element competes with other sequencing challengers including Singular Genomics (G4 benchtop platform), Ultima Genomics (wafer-based UG 100), and MGI/Complete Genomics, all trying to erode Illumina's position with new chemistry or hardware. As of the July 2026 assessment, none of these smaller rivals is documented as actively pulling customers away from Element itself.
Is Element Biosciences in financial trouble?: There's no evidence of imminent financial trouble as of the July 2026 assessment: Element's 2023 annual revenue exceeded $25M, its Series D topped $277M in mid-2024, and Samsung added $175M in a Series E round as of June 9, 2026. Cash burn is still flagged as an unresolved factor in its overall too-close-to-call standing, so the situation bears watching rather than being settled either way.
Is Element Biosciences at risk from AI?: AI does not appear to be a threat to Element Biosciences; the assessment lists its AI threat status as not applicable. If anything, AI models need more genomic data to train on, which tends to grow rather than shrink demand for sequencing platforms like AVITI and VITARI.
Can Illumina copy or crush Element Biosciences?: Illumina could try to copy elements of Element's approach, and the giant-threat status is marked as shipped, meaning Illumina has already moved to compete directly through litigation and pricing. However, Element has genuine legal cover: it won a German patent injunction against Illumina on July 14, 2026, and survived a US antitrust suit that was dismissed on May 28, 2026, with precedent for challengers beating Illumina in court, as MGI/Complete Genomics won a $333.8M verdict in 2024.

Timeline

2026-07-14Munich court rules Illumina infringes Element patent, enjoins MiSeq/MiSeqDx in Germany
2026-06-17Element achieves ISO 13485 certification ahead of AVITI Dx diagnostics push
2026-06-09Element announces upsized Series E with $175M from Samsung Electronics
2026-02-25Element unveils VITARI sequencer targeting 10B reads/run and $100 genome
2026-01-12Element previews AVITI Dx and new $100 genome platform at JPM Healthcare
2025-08-07Element adds Chief People Officer, VP Customer Support, VP Engineering
2025-04-24Element accelerates rollout of AVITI24 Direct In Sample Sequencing (DISS)
2024-07-01Element closes $277M Series D funding round
2024-01-08Element reports over $25M 2023 revenue, 160+ AVITI orders, 112 installs
2022-03-01Element launches AVITI benchtop sequencer using avidite base chemistry

Head to head

Element Biosciences vs Illumina Element Biosciences vs Singular Genomics

Revision history

30 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Charles River Laboratories Bio-Techne Corporation Vizgen, Inc.